Scotton P.G.; Pea F.; Giobbia M.; Baraldo M.; Vaglia A.; Furlanut M., Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis, «CLINICAL INFECTIOUS DISEASES», 2001, 33, pp. e109 - e111 [articolo]
Baraldo M.; Pea F.; Poz D.; Albanese M.C.; Livi U.; Furlanut M., Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients, «TRANSPLANTATION PROCEEDINGS», 2001, 33, pp. 3151 - 3153 [articolo]
Baraldo M.; Pea F.; Poz D.; Furlanut M., Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, «PHARMACOLOGICAL RESEARCH», 2001, 43, pp. 547 - 551 [articolo]
Brusaferro S.; Rinaldi O.; Pea F.; Faruzzo A.; Barbone F., Protocol implementation in hospital infection control practice: An Italian experience of preoperative antibiotic prophylaxis, «THE JOURNAL OF HOSPITAL INFECTION», 2001, 47, pp. 288 - 293 [articolo]
Pea F.; Brollo L.; Lugano M.; Pos L.D.; Furlanut M., Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration, «THERAPEUTIC DRUG MONITORING», 2001, 23, pp. 587 - 588 [replica/breve intervento]
Pea F.; Milaneschi R.; Baraldo M.; Lugatti E.; Talmassons G.; Furlanut M., Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring, «THERAPEUTIC DRUG MONITORING», 2000, 22, pp. 386 - 391 [articolo]
PEA, Federico; PORRECA2, L2; BARALDO, Massimo; FURLANUT, Mario, High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2000, 45, pp. 329 - 335 [articolo]
Pea F.; Russo D.; Michieli M.; Baraldo M.; Ermacora A.; Damiani D.; Baccarani M.; Furlanut M., Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia, «CANCER CHEMOTHERAPY AND PHARMACOLOGY», 2000, 46, pp. 279 - 286 [articolo]
Ermacora, A; Michieli, M; Pea, F; Visani, G; Bucalossi, A; Russo, D, Liposome encapsulated daunorubicin (daunoxome) for acute leukemia, «HAEMATOLOGICA», 2000, 85, pp. 324 - 325 [replica/breve intervento]
PEA, Federico; POZ, Donatella; BARALDO, Massimo; FURLANUT, Mario, Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function. Multiple daily doses may be preferable, «CLINICAL DRUG INVESTIGATION», 2000, 19, pp. 213 - 218 [replica/breve intervento]
Pea F.; Furlanut M.; Bianchi L., Systemic vancomycin overexposure in a patient with spinal cord injury who had staphylococcal sepsis and Clostridium difficile colitis, «THERAPEUTIC DRUG MONITORING», 2000, 22, pp. 233 - 234 [replica/breve intervento]
Baraldo M.; Ferraccioli G.; Pea F.; Gremese E.; Furlanut M., Cyclosporine a pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy, «PHARMACOLOGICAL RESEARCH», 1999, 40, pp. 483 - 486 [articolo]
Pea F.; Milaneschi R.; Baraldo M.; Talmassons G.; Furlanut M., Isoniazid and its hydrazine metabolite in patients with tuberculosis, «CLINICAL DRUG INVESTIGATION», 1999, 17, pp. 145 - 154 [articolo]
Michieli M.; Damiani D.; Ermacora A.; Masolini P.; Michelutti A.; Michelutti T.; Russo D.; Pea F.; Baccarani M., Liposome-encapsulated daunorubicin for PGP-related multidrug resistance, «BRITISH JOURNAL OF HAEMATOLOGY», 1999, 106, pp. 92 - 99 [articolo]
Pea F.; Damiani D.; Michieli M.; Ermacora A.; Baraldo M.; Russo D.; Fanin R.; Baccarani M.; Furlanut M., Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 1999, 55, pp. 361 - 368 [articolo]
